retatrutide phase 2 trial dosing schedule clinical retatrutide Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized 2a Trial Data Dosing : – Retatrutide Dosing: Early Clinical Trial

Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials

Twice weekly dosing reduces peak concentrations by approximately 28% and brings the peak-to-trough ratio down to 2.1

Intestinal phase of gastric secretion', Journal of Experimental Physiology , 15,55-68

Diabetes Care (2014) 37:216876

Change is on the horizon, though

Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial